Use of Mtaase Deficiency in Cancer Treatment


NIH 1992 R01 CA	Use of Mtaase Deficiency in Cancer Treatment Fitchen, John H. / Epitope, Inc.
NIH 1991 R01 CA	Use of Mtaase Deficiency in Cancer Treatment Fitchen, John H. / Epitope, Inc.
NIH 1990 R01 CA	Use of Mtaase Deficiency in Cancer Treatment Fitchen, John H. / Oregon Health and Science University
NIH 1990 R01 CA	Use of Mtaase Deficiency in Cancer Treatment Fitchen, John H. / Epitope, Inc.
NIH 1989 R01 CA	Use of Mtaase Deficiency in Cancer Treatment Fitchen, John H. / Oregon Health and Science University
NIH 1988 R01 CA	Use of Mtaase Deficiency in Cancer Treatment Fitchen, John H. / Oregon Health and Science University
NIH 1987 R01 CA	Use of Mtaase Deficiency in Cancer Treatment Fitchen, John H. / Oregon Health and Science University
NIH 1986 R01 CA	Use of Mtaase Deficiency in Cancer Treatment Fitchen, John H. / Oregon Health and Science University

Sherman, K J; Daling, J R; McKnight, B et al. (1994) Hormonal factors in vulvar cancer. A case-control study. J Reprod Med 39:857-61

Sherman, K J; Daling, J R; Chu, J et al. (1991) Genital warts, other sexually transmitted diseases, and vulvar cancer. Epidemiology 2:257-62

Riscoe, M K; Brouns, M C; Fitchen, J H (1989) Purine metabolism as a target for leukemia chemotherapy. Blood Rev 3:162-73